Bacterial terpene biosynthesis: challenges and opportunities for pathway engineering

• Eric J. N. Helfrich,
• Geng-Min Lin,
• Christopher A. Voigt and
• Jon Clardy

Beilstein J. Org. Chem. 2019, 15, 2889–2906, doi:10.3762/bjoc.15.283

• major product, while few of them are known to produce multiple products [1][50][76][114][115][116][117]. Among them, 10-epi-cubebol synthase from Sorangium cellulosum Soce56 is the most prolific bacterial TC known. It produces at least 25 different sesquiterpene skeletons in addition to 10-epi-cubebol

Lanyamycin, a macrolide antibiotic from Sorangium cellulosum, strain Soce 481 (Myxobacteria)

• Lucky S. Mulwa,
• Rolf Jansen,
• Dimas F. Praditya,
• Kathrin I. Mohr,
• Patrick W. Okanya,
• Joachim Wink,
• Eike Steinmann and
• Marc Stadler

Beilstein J. Org. Chem. 2018, 14, 1554–1562, doi:10.3762/bjoc.14.132

• Bochum, Germany 10.3762/bjoc.14.132 Abstract Lanyamycin (1/2), a secondary metabolite occurring as two epimers, was isolated from the myxobacterium Sorangium cellulosum, strain Soce 481. The structures of both epimers were elucidated from HRESIMS and 1D and 2D NMR data and the relative configuration of

• and the human nasopharyngeal cell line KB3 with IC50 values of 3.1 and 1.5 μM, respectively, and also suppressed the growth of the Gram-positive bacterium Micrococcus luteus. Keywords: antimicrobial; HCV; lanyamycin; macrolide; Sorangium cellulosum; Introduction Viral hepatitis (HCV) has recently

• of which were found to exert anti-HIV activity while sorazolones, argyrins and tubulysins showed antitumor activity or cytotoxicity [4][5][6][7][8]. In our studies on the secondary metabolites of Sorangium cellulosum (strain Soce 481), we observed strong antifungal activity in the raw extract. On RP

Mechanistic investigations on six bacterial terpene cyclases

• Patrick Rabe,
• Thomas Schmitz and
• Jeroen S. Dickschat

Beilstein J. Org. Chem. 2016, 12, 1839–1850, doi:10.3762/bjoc.12.173

• synthase. Furthermore, a 10-epi-cubebol synthase was recently identified from Sorangium cellulosum [45], but this enzyme exhibits only poor sequence identity (29%) to the S. roseum (+)-4-epi-cubebol synthase and must have evolved independently. Incubation of FPP with a terpene cyclase from Streptomyces

Marine-derived myxobacteria of the suborder Nannocystineae: An underexplored source of structurally intriguing and biologically active metabolites

• Antonio Dávila-Céspedes,
• Peter Hufendiek,
• Max Crüsemann,
• Till F. Schäberle and
• Gabriele M. König

Beilstein J. Org. Chem. 2016, 12, 969–984, doi:10.3762/bjoc.12.96

• genome of Sorangium cellulosum So0157-2 is the largest bacterial genome reported to date [1]. Myxobacteria are able to glide over surfaces in swarms in order to facilitate heterotrophic nutrition on macromolecules as well as on whole microorganisms, a distinctive trait of these bacteria [2]. Additionally

• neighbor-joining tree is based on a multiple sequence alignment (MSA) of the 16S rDNA sequences. The terrestrial myxobacteria Myxococcus xanthus DK1622 and Sorangium cellulosum Soce56 as well as Escherichia albertii DM104 are included for comparison (see Supporting Information File 1 for the sequences used

Antibiotics from predatory bacteria

• Juliane Korp,
• María S. Vela Gurovic and
• Markus Nett

Beilstein J. Org. Chem. 2016, 12, 594–607, doi:10.3762/bjoc.12.58

• in size and contain between 7,285 (Myxococcus fulvus HW-1) and 11,599 (Sorangium cellulosum So0157-2) protein-coding sequences (Table 1) [42][43][44][45][46][47]. In comparison, the genome of the standard laboratory bacterium Escherichia coli comprises only 4.6 Mbp of DNA [48]. With a single

• the genome size. The largest number of secondary metabolite gene clusters was found in Corallococcus coralloides DSM 2259 and not in the two Sorangium cellulosum strains, although the latter feature significantly larger genomes (Table 1). When the number of detected loci is related to the genome size

A reductive coupling strategy towards ripostatin A

• Kristin D. Schleicher and
• Timothy F. Jamison

Beilstein J. Org. Chem. 2013, 9, 1533–1550, doi:10.3762/bjoc.9.175

• ; Introduction The ripostatins (A, B, and C) are a family of antibiotic natural products, isolated in 1995 by Höfle and colleagues from cultures of the myxobacterium Sorangium cellulosum (Figure 1) [1][2]. Ripostatins A and B are active against Gram-positive bacteria due to their inhibition of bacterial